Olaparib has been deemed safe in combination with carboplatin/paclitaxel in advanced ovarian cancer.
Olaparib with carboplatin and paclitaxel was found to be safe for the treatment of patients with relapsed ovarian cancer.
A drug originally used to treat ovarian cancer has shown promising results in patients with advanced peritoneal cancers during a phase I clinical trial.
Ovarian cancer was found to spread via circulating tumor cells (CTCs) in the bloodstream, homing in on the omentum, a sheet of tissue that covers and supports the abdominal organs. Researchers found that the CTCs rely on HER3 to find their way to omentum.
A new combination of medications for treatment of recurrent ovarian cancer showed improved response rates, increased the rate of tumor shrinkage, and prolonged the time until cancers recurred
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|